Amylin gene promoter mutations predispose to type 2 diabetes in New Zealand Maori

Diabetologia

Volumn 46, Issue 4, 2003, Pages 574-578

  Poa, N R ^a,b   Cooper, G J S ^a   Edgar, P F ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Amylin gene; Caucasian; Maori; Mutation; New Zealand; Polymorphism; Type 2 diabetes

Indexed keywords

AMYLIN;

ADULT; AGED; ARTICLE; ASIA; CHINESE; CONTROLLED STUDY; EXON; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; INTRON; JAPAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NEW ZEALAND; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0038293280     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1068-x     Document Type: Article

References (24)

1. NZHIS (1997) Mortality and demographic data 1997. NZHIS Wellington
2. Simmons D, Gatland B, Fleming C, Leakehe L, Scragg R (1994) Prevalence of known diabetes in a multiethnic community. N Z Med J 107:219-222
3. Jun H-E, Bae HY, Lee BR et al. (1999) Pathogenesis of non-insulin-dependent (type 2) diabetes mellitus (NIDDM) - genetic predisposition and metabolic abnormalities. Adv Drug Del Rev 35:157-177
4. Scragg R, Baker J, Metcalf P (1991) Prevalence of diabetes mellitus and impaired glucose tolerance in a New Zealand multiracial workforce. N Z Med J 104:395-397
5. Simmons D, Shaw LM, Scott DJ, Kenealy T, Scragg RK (1994) Diabetic nephropathy and microalbuminuria in the community. The South Auckland Diabetes Survey. Diabetes Care 17:1404-1410
6. Shaw JT, Lovelock PK, Kesting JB et al. (1998) Novel susceptibility gene for late-onset NIDDM is localized to human chromosome 12q. Diabetes 47:1793-1796
7. Su B, Jin L, Underhill P et al. (2000). Polynesian origins: insights from the Y chromosome. Proc Natl Acad Sci USA 97:8225-8228
8. Lum JK, Cann RL (2000) mtDNA lineage analyses: origins and migrations of Micronesians and Polynesians. Am J Phys Anthropol 113:151-168
9. Sakagashira S, Sanke T, Hanabusa T et al. (1996) Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 45:1279-1281
10. Lee SC, Hashim Y, Li JK et al. (2001) The islet amyloid polypeptide (amylin) gene S20G mutation in Chinese subjects: evidence for associations with type 2 diabetes and cholesterol levels. Clin Endocrinol (Oxf) 54:541-546
11. Birch CL, Fagan LJ, Armstrong MJ, Turnbull DM, Walker M (1997) The S20G islet-associated polypeptide gene mutation in familial NIDDM. Diabetologia 40:1113
12. Hart LM, Stolk RP, Dekker JM et al. (1999) Prevalence of variants in candidate genes for type 2 diabetes mellitus in The Netherlands: the Rotterdam study and the Hoorn study. J Clin Endocrinol Metab 8:1002-1006
13. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628-8632
14. Clark A, Koning EJ de, Hatterstey AT, Hansen BC, Yajnik CS, Pouton J (1995) Pancreatic pathology in non-insulin-dependent diabetes (NIDDM).Diabetes Res Clin Pract [Suppl] 28:S39-S47
15. Hiddinga HJ, Eberhardt NL (1999) Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. Am J Pathol 154:1077-1088
16. Sakagashira S, Hiddinga HJ, Tateishi K et al. (2000) S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin. Am J Pathol 157:2101-2109
17. NZHIS (1996) Recording patient information: ethnicity. Wellington, NZHIS
18. Kajio H, Kobayashi T, Hara M et al. (1992) Islet amyloid polypeptide (IAPP) gene analysis in a Japanese diabetic with marked islet amyloid deposition. Diabetes Res Clin Pract 15:45-48
19. Wingender E, Chen X, Hehl R et al. (2000) TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res 28:316-319
20. Tokoyama Y, Kanatsuke A, Suzuki Y et al. (1994) Islet amyloid polypeptide: no evidence of abnormal promoter region in thirty five type 2 diabetic patients. Diabetes Res Clin Pract 22:99-105
21. Hani EH, Stoffers DA, Chevre JC et al. (1999) Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 104:R41-R48
22. Weng J, Macfarlane WM, Lehto M et al. (2001) Functional consequences of mutations in the MODY4 gene (IPF-1) and coexistence with MODY3 mutations. Diabetologia 44:249-258
23. Carty MD, Lillquist JS, Peshavaria M, Stein R, Soeller WC (1997) Identification of cis- and trans-active factors regulating human islet amyloid polypeptide gene expression in pancreatic beta-cells. J Biol Chem 272:11986-11993
24. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036-5040